The synthesis Of DNA, RNA and protein in L121O cells was inhibited by HHO7A in a dose-dependentand time-dependent way. HHO7A shOwed much stronger inhibitory effect on [3H]-thymidine incorporationthan that on [3H]-urid...The synthesis Of DNA, RNA and protein in L121O cells was inhibited by HHO7A in a dose-dependentand time-dependent way. HHO7A shOwed much stronger inhibitory effect on [3H]-thymidine incorporationthan that on [3H]-uridine or [3H]-tyrosine incorporation. The methods of shift of absorption spectrum,shift of fluorescence emission spectrum and excitation spectrum, and isotope technique were used to investigate the mechanism of actiOn of HHO7A on DNA synthesis. The results suggested thaT the action ofHHO7A on DNA synthesis was nOt probably due to direct damage to the DNA template, it might mainlyact by interfering with the metabolism of DNA.展开更多
Colorectal cancer is the second most common malignant tumor in China.The FOLFOXIRI regimen,which combines 5-fluorouracil/leucovorin,oxaliplatin,and irinotecan,is a high-intensity and highly effective chemotherapy regi...Colorectal cancer is the second most common malignant tumor in China.The FOLFOXIRI regimen,which combines 5-fluorouracil/leucovorin,oxaliplatin,and irinotecan,is a high-intensity and highly effective chemotherapy regimen.However,the original regimen is poorly tolerated in Chinese patients.In order to promote the standardization and rational application of FOLFOXIRI regimen by clinicians in China,the“Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan(CPT-11),Oxaliplatin(LOHP),Continuous Infusion 5-Fluorouracil,and Leucovorin for Colorectal Cancer”was formulated by the Committee of Colorectal Cancer in Chinese Southwest Oncology Group.Based on the mechanism underlying the combined three drugs and toxicity profile,the dosage of Chinese modified FOLFOXIRI(cmFOLFOXIRI)regimen and the management of adverse reactions are proposed.This consensus recommended that the FOLFOXIRI regimen be used in neoadjuvant,conversion,and palliative therapy for colorectal cancer under specific conditions.This consensus aimed to drive the application of cmFOLFOXIRI in the field of colorectal cancer in order to bring benefits to colorectal cancer patients.展开更多
文摘The synthesis Of DNA, RNA and protein in L121O cells was inhibited by HHO7A in a dose-dependentand time-dependent way. HHO7A shOwed much stronger inhibitory effect on [3H]-thymidine incorporationthan that on [3H]-uridine or [3H]-tyrosine incorporation. The methods of shift of absorption spectrum,shift of fluorescence emission spectrum and excitation spectrum, and isotope technique were used to investigate the mechanism of actiOn of HHO7A on DNA synthesis. The results suggested thaT the action ofHHO7A on DNA synthesis was nOt probably due to direct damage to the DNA template, it might mainlyact by interfering with the metabolism of DNA.
基金supported by The National Key Research and Development Plan of China[2019YFC1316003].
文摘Colorectal cancer is the second most common malignant tumor in China.The FOLFOXIRI regimen,which combines 5-fluorouracil/leucovorin,oxaliplatin,and irinotecan,is a high-intensity and highly effective chemotherapy regimen.However,the original regimen is poorly tolerated in Chinese patients.In order to promote the standardization and rational application of FOLFOXIRI regimen by clinicians in China,the“Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan(CPT-11),Oxaliplatin(LOHP),Continuous Infusion 5-Fluorouracil,and Leucovorin for Colorectal Cancer”was formulated by the Committee of Colorectal Cancer in Chinese Southwest Oncology Group.Based on the mechanism underlying the combined three drugs and toxicity profile,the dosage of Chinese modified FOLFOXIRI(cmFOLFOXIRI)regimen and the management of adverse reactions are proposed.This consensus recommended that the FOLFOXIRI regimen be used in neoadjuvant,conversion,and palliative therapy for colorectal cancer under specific conditions.This consensus aimed to drive the application of cmFOLFOXIRI in the field of colorectal cancer in order to bring benefits to colorectal cancer patients.
